$9.63
-0.77-7.40%
At Close: -
$10.75
1.1211.63%
After Hours: Jul 23, 5:50 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Atara Biotherapeutics (NASDAQ:ATRA) Stock, Analyst Ratings, Price Targets, Forecasts
Atara Biotherapeutics Inc has a consensus price target of $12.77 based on the ratings of 12 analysts. The high is $28 issued by HC Wainwright & Co. on September 26, 2023. The low is $1 issued by Mizuho on November 9, 2023. The 3 most-recent analyst ratings were released by Goldman Sachs, Stifel, and Goldman Sachs on July 17, 2024, April 1, 2024, and November 10, 2023, respectively. With an average price target of $4.6 between Goldman Sachs, Stifel, and Goldman Sachs, there's an implied -57.21% downside for Atara Biotherapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Stifel
Mizuho
HC Wainwright & Co.
Citigroup
1calculated from analyst ratings
Analyst Ratings for Atara Biotherapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/17/2024 | Buy Now | 2.33% | Goldman Sachs | Tommie Reerink | $12.5 → $11 | Maintains | Sell | Get Alert |
| 05/22/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns | — | Reiterates | → Neutral | Get Alert |
| 04/01/2024 | Buy Now | -78.6% | Stifel | Benjamin Burnett | $120 → $57.5 | Maintains | Hold | Get Alert |
| 11/10/2023 | Buy Now | -95.35% | Goldman Sachs | Tommie Reerink | $75 → $12.5 | Maintains | Sell | Get Alert |
| 11/09/2023 | Buy Now | — | Evercore ISI Group | Michael DiFiore | — | Downgrade | Outperform → In-Line | Get Alert |
| 11/09/2023 | Buy Now | — | HC Wainwright & Co. | Robert Burns | — | Downgrade | Buy → Neutral | Get Alert |
| 11/09/2023 | Buy Now | -90.7% | Mizuho | Salim Syed | $775 → $25 | Downgrade | Buy → Neutral | Get Alert |
| 09/26/2023 | Buy Now | 160.47% | HC Wainwright & Co. | — | → $700 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | Buy Now | -86.98% | Citigroup | Yigal Nochomovitz | $50 → $35 | Maintains | Sell | Get Alert |
| 08/09/2023 | Buy Now | 132.56% | EF Hutton | Anthony Butler | $625 → $625 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | Buy Now | 160.47% | HC Wainwright & Co. | Robert Burns | $675 → $700 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 86.05% | Canaccord Genuity | John Newman | $1250 → $500 | Maintains | Buy | Get Alert |
| 02/09/2023 | Buy Now | 132.56% | EF Hutton | Anthony Butler | $625 → $625 | Reiterates | → Buy | Get Alert |
| 02/09/2023 | Buy Now | 151.16% | HC Wainwright & Co. | Robert Burns | $725 → $675 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | 188.37% | Mizuho | Salim Syed | → $775 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | Buy Now | 132.56% | EF Hutton | Tony Butler | → $625 | Initiates | → Buy | Get Alert |
| 08/16/2022 | Buy Now | 188.37% | Mizuho | Salim Syed | $975 → $775 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | -72.09% | Goldman Sachs | Tommie Reerink | $100 → $75 | Maintains | Sell | Get Alert |
| 07/20/2022 | Buy Now | -72.09% | Citigroup | Yigal Nochomovitz | → $75 | Downgrade | Neutral → Sell | Get Alert |
| 07/13/2022 | Buy Now | -6.98% | JP Morgan | Anupam Rama | → $250 | Downgrade | Overweight → Neutral | Get Alert |
| 07/13/2022 | Buy Now | -53.49% | Stifel | Benjamin Burnett | $400 → $125 | Downgrade | Buy → Hold | Get Alert |
| 05/24/2022 | Buy Now | -62.79% | Goldman Sachs | Salveen Richter | $125 → $100 | Maintains | Sell | Get Alert |
| 05/23/2022 | Buy Now | 169.77% | HC Wainwright & Co. | Robert Burns | $775 → $725 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | -25.58% | Citigroup | Yigal Nochomovitz | $575 → $200 | Downgrade | Buy → Neutral | Get Alert |
| 03/28/2022 | Buy Now | 104.65% | JP Morgan | Anupam Rama | $675 → $550 | Maintains | Overweight | Get Alert |
| 01/03/2022 | Buy Now | 151.16% | JP Morgan | Anupam Rama | $650 → $675 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Atara Biotherapeutics (ATRA) stock?
The latest price target for Atara Biotherapeutics (NASDAQ:ATRA) was reported by Goldman Sachs on July 17, 2024. The analyst firm set a price target for $11.00 expecting ATRA to rise to within 12 months (a possible 2.33% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atara Biotherapeutics (ATRA)?
The latest analyst rating for Atara Biotherapeutics (NASDAQ:ATRA) was provided by Goldman Sachs, and Atara Biotherapeutics maintained their sell rating.
When was the last upgrade for Atara Biotherapeutics (ATRA)?
There is no last upgrade for Atara Biotherapeutics
When was the last downgrade for Atara Biotherapeutics (ATRA)?
The last downgrade for Atara Biotherapeutics Inc happened on November 9, 2023 when Evercore ISI Group changed their price target from N/A to N/A for Atara Biotherapeutics Inc.
When is the next analyst rating going to be posted or updated for Atara Biotherapeutics (ATRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on July 17, 2024 so you should expect the next rating to be made available sometime around July 17, 2025.
Is the Analyst Rating Atara Biotherapeutics (ATRA) correct?
While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a maintained with a price target of $12.50 to $11.00. The current price Atara Biotherapeutics (ATRA) is trading at is $10.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.